Q-omics provides the consensus-scored MT-RNR1 profile across patient tissues and cancer cell-line models. MT-RNR1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MT-RNR1 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, MT-RNR1 RNA expression shows 18,763 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight ACC, HNSC, and KIRP as cancer lineages where MT-RNR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-RNR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-RNR1 survival associations across molecular data types. MT-RNR1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-RNR1 RNA expression–survival associations across cancer types. High MT-RNR1 expression shows unfavorable associations in LUAD and UCS, but favorable associations in ACC, UVM, LGG and KICH. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MT-RNR1 RNA expression.
This table summarizes MT-RNR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MT-RNR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-RNR1 shows lower tumor expression in HNSC, KIRC, COAD, BRCA, STAD and BLCA. The HNSC box plot shows higher MT-RNR1 RNA expression in normal versus tumor tissue (log2 FC = −1.576, t-test p < 0.001).
This table shows molecular features associated with MT-RNR1 in patient tissues and cancer cell lines. In patient samples, MT-RNR1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
